# Teva Laboratories UK Ltd Pension Scheme

Teva Laboratories UK Ltd Pension Scheme is a Pension Fund based in Castleford, United Kingdom.

## Overview

- **Organization type:** Pension Fund
- **Headquarters:** Castleford, United Kingdom
- **Region:** Europe
- **Address:** Castleford, United Kingdom
- **Assets under management:** Undisclosed
- **LinkedIn:** https://linkedin.com/company/tef-laboratories-ltd

## Regulatory record

- **Reports private funds:** No

## About

The scheme exists as a legacy corporate defined-benefit plan sponsored by Teva UK Limited, the British subsidiary of Israel-headquartered Teva Pharmaceutical Industries Ltd. As Teva's global business contended with patent expirations on Copaxone, debt burdens from the Allergan generics acquisition, and opioid litigation in the US, this individual UK plan represents one node in a complex web of statutory pension obligations the parent company must fund. The plan is based in Castleford, West Yorkshire. The scheme's investment strategy is anchored in a diversified multi-asset framework typical of UK corporate defined-benefit plans of its scale. While precise allocations are not public, comparable schemes allocate across UK and global equities, investment-grade corporate bonds, gilts, and increasingly to alternative assets such as private credit, infrastructure, and real estate to improve liability-matching yields. The plan's ultimate investment posture is shaped by the trustees in consultation with Teva UK Limited, aiming to satisfy the statutory funding requirements set by The Pensions Regulator while minimizing cash calls on the sponsor. Richard Daniell, as a former Senior Director at Teva UK Limited, has been associated with the scheme's oversight. Teva Pharmaceutical Industries Ltd remains the ultimate sponsoring parent, meaning the scheme's funded status is a line item in Teva's global financial disclosures. Historically, multinational pharmaceutical companies with large UK workforces have maintained such DB plans, and Teva's presence in the UK—which includes distribution, packaging, and formerly manufacturing—created this obligation. There is no evidence the plan operates any adjacent direct-investment vehicles, co-investment clubs, or affiliated foundations; its ties to organizations like Rethink Mental Illness and The Neurological Alliance suggest corporate-level charitable partnerships rather than plan-specific philanthropic structures. Structurally, this plan is a pure captive asset owner, not a commercial or multi-employer fund. Its governance model separates the trustee board's fiduciary duty to members from the corporate sponsor's balance-sheet interests, a classic UK DB architecture under the Pensions Act. Unlike large standalone public pension funds or outsourced CIO-managed pools, this scheme's investment decisions are ultimately constrained by the sponsor's own credit profile and cash-flow needs—a dynamic that became acute when Teva's leverage peaked in the late 2010s.

## Sectors

- Diversified

## People

- Richard Daniell — Former Senior Director, Teva UK Limited (primary contact for the scheme)

## Questions

### Who sponsors the Teva Laboratories UK Ltd Pension Scheme?

The scheme is sponsored by Teva UK Limited, the British operating subsidiary of Teva Pharmaceutical Industries Ltd. Teva Pharmaceutical Industries is the ultimate corporate parent and bears ultimate responsibility for the scheme's funded status under UK pension law and consolidated financial reporting.

### How is the pension scheme governed?

The plan operates under a trustee board model standard for UK defined-benefit schemes, where trustees have a fiduciary duty to plan members. The sponsor, Teva UK Limited, works with the trustees to agree on funding and investment strategies, all regulated by The Pensions Regulator.

### Is this scheme open to new members?

Most UK corporate defined-benefit pension schemes, particularly those sponsored by large multinationals like Teva, have closed to new entrants or future accrual. The specific accrual status of this Teva plan is not publicly confirmed, but it is considered a legacy liability.

### How does Teva's global financial health affect the UK pension plan?

Because Teva Pharmaceutical Industries Ltd is the ultimate parent, its credit profile directly influences the scheme's security. Teva's high leverage following the $40.5 billion Allergan generics acquisition in 2016, and its subsequent multi-year restructuring and debt-reduction program, have been critical factors for the trustees in assessing sponsor covenant strength and negotiating funding contributions (per Teva annual reports, 2017-2024).

## Related profiles

- [Temple University Post-Retirement Benefits Trust](https://altss.com/profile/temple-university-post-retirement-benefits-trust)
- [Texas Exes](https://altss.com/profile/texas-exes)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/teva-laboratories-uk-ltd-teva-laboratories-uk-ltd-pension-scheme

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology